Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 3,275 shares, a decline of 77.2% from the May 14th total of 14,337 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 21,621 shares, the short-interest ratio is presently 0.2 days.

Barinthus Biotherapeutics Price Performance

BRNS stock traded down $0.02 during midday trading on Thursday, hitting $0.67. The company’s stock had a trading volume of 15,054 shares, compared to its average volume of 57,770. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $2.92. The company’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.67. The stock has a market capitalization of $27.37 million, a P/E ratio of -0.52 and a beta of -0.40.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.14.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Rangeley Capital LLC boosted its stake in Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares during the period. Renaissance Technologies LLC boosted its position in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its position in shares of Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares in the last quarter. 25.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.